Long-term mortality among women with epithelial ovarian cancer: a population-based study in British Columbia, Canada

Abstract

ObjectivesAmong women with epithelial ovarian cancer (EOC), histotype is one of the major prognostic factors. However, few data are available on histotype- specific survival and mortality estimates among these patients. We therefore examined survival and causes of death among women with EOC by histotype.MethodsA population- based cohort including all ovarian cancer patients diagnosed in British Columbia (BC) between 1990 and 2014 was built using population-based administrative datasets. We compared causes of death within histotypes, by age at diagnosis, BRCA status, and time since diagnosis.ResultsA total of 6975 women were identified as having been diagnosed with EOC between 1990 and 2014 in BC. The most common cause of death among these women was ovarian cancer until 10 years post diagnosis when other causes surpassed ovarian cancer as the leading cause of death. Among women with serous EOCs, ovarian cancer was the leading cause of death 12 years after diagnosis, whereas ovarian cancer was the leading cause of death for 8 years among women with non- serous EOCs. Among women with serous EOCs, ovarian cancer was the leading cause of death for 12 years among younger women (< 60 years of age) compared to 8 years among women > = 60 years of age, and those with BRCA mutations were more likely to die from ovarian cancer than those without a BRCA mutation.ConclusionsWithin 10 years from diagnosis, ovarian cancer is the leading cause of death among women diagnosed with EOC.Electronic supplementary materialThe online version of this article (10.1186/s12885-018-4970-9) contains supplementary material, which is available to authorized users.

Real-world hematological adverse events in Chinese patients with advanced ovarian cancer treated with an individualized starting dose of niraparib

“…The preferred treatment for OC is surgery combined with platinum-based chemotherapy (2,3). Although clinical remission can be achieved after the initial treatment, most OC cases relapse within 3 years, and 5-year survival is only about 40-50% (4,5). The focus of clinical management of OC is to prolong the efficacy of platinum-containing chemotherapy and delay recurrence (2,3).…”

Construction autophagy-related prognostic risk signature to facilitate survival prediction, individual treatment and biomarker excavation of epithelial ovarian cancer patients

“…Some pharmaceutical agents targeting autophagy have been proved effective in EOC patients [ 24 , 25 ]. Up to now, histological grade and stage remain the strongest prognostic evaluation tools in EOC [ 26 ]. Make use of a prognostic model which constructed based on the specific molecule can improve the understanding of the molecular mechanism of EOC, aid the development of more specific therapies, and identify novel biomarkers [ 27 , 28 ].…”

Death of 43 Indonesian women with ovarian cancer: A case series

“…Based on the most recent literature, most ovarian cancer patients died of carcinomatosis. Aggressive cancer growth causes spread to the pelvis and abdomen, so that the patient experiences intestinal obstruction and failure of the surrounding organs, which ultimately results in the patient’s death [ 17 , 18 ].…”